BIOMARKER:

DNMT3A mutation + FLT3-ITD mutation

Entrez ID:

Related biomarkers:

‹

›

DNMT3A mutation + FLT3-ITD mutation DNMT3A mutation + FLT3-ITD mutation	Acute Myelogenous Leukemia AML	DNMT3A mutation + FLT3-ITD mutation DNMT3A mutation + FLT3-ITD mutation	Acute Myelogenous Leukemia AML	cytarabine Resistant: C3 – Early Trials	cytarabine Resistant: C3 – Early Trials
DNMT3A mutation + FLT3-ITD mutation DNMT3A mutation + FLT3-ITD mutation	Acute Myelogenous Leukemia AML	DNMT3A mutation + FLT3-ITD mutation DNMT3A mutation + FLT3-ITD mutation	Acute Myelogenous Leukemia AML	gilteritinib Sensitive: C3 – Early Trials	gilteritinib Sensitive: C3 – Early Trials
DNMT3A mutation + FLT3-ITD mutation DNMT3A mutation + FLT3-ITD mutation	Acute Myelogenous Leukemia AML	DNMT3A mutation + FLT3-ITD mutation DNMT3A mutation + FLT3-ITD mutation	Acute Myelogenous Leukemia AML	quizartinib Sensitive: C3 – Early Trials	quizartinib Sensitive: C3 – Early Trials
DNMT3A mutation + FLT3-ITD mutation DNMT3A mutation + FLT3-ITD mutation	Acute Myelogenous Leukemia AML	DNMT3A mutation + FLT3-ITD mutation DNMT3A mutation + FLT3-ITD mutation	Acute Myelogenous Leukemia AML	venetoclax Sensitive: C4 – Case Studies	venetoclax Sensitive: C4 – Case Studies